Trisomy 16 accounts for 1-2% or more of all first trimester miscarriages (Neiswanger et al., 2006) , and the abortuses show empty sacs, disorganized embryos, or minimal embryonic development (Benn, 1998) . Trisomy 16 occurs almost exclusively as a non-disjunction event in maternal meiosis I, while gestational trisomy 16 mosaicism is caused by mitotic non-disjunction (Neiswanger et al., 2006) . Trisomy 16 mosaicism develops through the postzygotic loss of one copy of chromosome 16, which rescues in parts of the trisomic embryo and/or placenta, and maternal uniparental disomy (UPD) is noted in approximately a third of such mosaicism cases. It is rarely observed in amniotic fluid cells, and is associated with a high risk of abnormal outcomes such as intrauterine growth retardation (IUGR), fetal death in utero, preeclampsia, preterm delivery, neonatal death, developmental delay, congenital heart defects, and other minor anomalies (Chareonsirisuthigul et al., 2014) .
Although trisomy 16 accounts for over 30% of cases of autosomal trisomy detected after spontaneous abortion, the detection of trisomy 16 mosaicisms by amniocentesis in the second trimester is rare (Neiswanger et al., 2006) .
Moreover, there remains a high probability of gestational abnormalities that result from trisomy 16 mosaicism. However, prenatal mosaic trisomy 16 cells are difficult to observe in fetal lymphocytes and are rarely confirmed in postnatal blood or other tissues (Benn, 1998) .
Here, we report a rare case of level III trisomy 16 mosai- Many published cases of mosaic trisomy 16 were identified as serum test positive (abnormal) using blood samples from the mothers (Neiswanger et al., 2006; Hidaka et al., 2009 ). In our case, elevated maternal serum alpha fetoprotein (MSAFP) levels (93.6 IU/mL) and abnormal triple test results (human chorionic gonadotropin (hCG) 647 IU/mL, unconjugated estriol (uE3) 0.8 ng/mL, and inhibin-A 473.9 pg/mL) were identified, which may reflect an association between low uE3 and growth retardation (Benn, 1998) . Although true mosaicism is usually associated with a high risk of mosaicism in the fetus (Haddad et al., 2013) , it should be carefully considered during prenatal diagnosis, as various degrees of mosaicism and specimen types can be observed depending on the gestational age.
The presence of trisomy 16 in amniocentesis is concerning, because it can result in low birth weight and a high risk of malformation (Langlois et al., 2006) . Trisomy 16 is also associated with IUGR, orofacial clefting, cardiac defects, renal dysplasia, imperforate anus, and many other anomalies (Yong et al., 2003; Sparks et al., 2017) , but the lack of published data on the long-term outcome of these children makes it difficult to counsel parents after a prenatal diagnosis of mosaicism for trisomy 16 (Langlois et al., 2006) .
The level of trisomy observed by amniocentesis is influenced by stochastic processes during cell proliferation, differentiation, and development (Yong et al., 2003) ; however, it is unclear whether low levels of trisomic cells are necessarily harmful or result in an abnormal phenotype.
Non-invasive prenatal genetic testing, also known as cell-free fetal DNA testing, has been used since 2011 to screen for common fetal aneuploidies, and is highly sensitive and specific, with a pooled sensitivity and specificity of 97.4 and 99.3%, respectively, for trisomy 13, 18, and 21 (Mardy and Wapner, 2016) . Since low-level true fetal mosaicism is possible even with a negative amniotic fluid culture, patients should be informed of this possibility (Grati et al., 2014) . The identification of trisomy mosaicism during prenatal diagnosis is often shrouded in uncertainty for the genetic counselor, and more importantly, for the parents. In up to 10% of all trisomy 16 pregnancies, postzygotic rescue may occur, enabling the pregnancy to continue with the usual complement of two copies of chromosome 16 (Sparks et al., 2017) . However, the risk of residual mosaicism exists with trisomic rescue, and limited information is available about the outcomes of pregnancies with trisomy 16 mosaicism (Sparks et al., 2017) ; this might be considered normal, but abnormalities and even in utero death could occur depending on the chromosomal status and the degree of mosaicism (Coman et al., 2010) . Regarding to verify rare mosaicism after amniocentesis, cordocentesis is another option that helps to counsel the parents about the prognosis (Post and Nijhuis, 1992; Schwartz & Raffel, 1992) .
Although studies of affected children and evaluation of important long-term outcomes remain to be conducted, there are several limitations to consider. Recently, a study found that the majority of children with trisomy 16 mosaicism and confined placental mosaicism during pregnancy or at birth exhibited normal neurodevelopmental outcomes and high quality of life scores (Generic Core Scales were used to measure health-related quality of life, as well as physical, emotional, social, and educational performance) (Sparks et al., 2017) . However, the role of UPD remains unclear, because this testing was only performed for eight cases in the cohort. Another study reported that a baby with trisomy 16 mosaicism had normal development, with postnatal growth retardation reversal (Coman et al., 2010) .
Therefore, parental counseling is prudent after a diagnosis of trisomy 16 mosaicism by amniocentesis.
Taken together, these results suggest that given the difficulty in predicting its outcomes, rare trisomy 16 mosaicism should be considered during prenatal genetic diagnosis and parental genetic counseling.
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